(Updated with Orange, BNP Paribas, SEB/Peugeot Invest, Puma, Croda International, abrdn)
*
Variation in futures on the CAC 40 0#FCE index:
*
Variation of futures on Stoxx 600 index 0#FXXP:
*
Values which are traded ex-dividend .EX.PA
*
Update on European markets .EUFR
Stocks to follow on Tuesday on the Paris Stock Exchange and in Europe:
* BOUYGUES BOUY.PA reported on Tuesday an increase in current operating profit in 2023, mainly driven by the contribution of Equasens.
➦ Bouygues posts current operating profit up in 2023
* ORANGE ORAN.PA and BNP PARIBAS BNPP.PA announced on Tuesday that they had signed several agreements which will allow BNP Paribas to provide its services to Orange Bank clients in France and Spain.
* GROUPE SEB SEBF.PA – PEUGEOT INVEST PEUG.PA announced on Tuesday that it had sold its 4.02% stake in Groupe SEB at the price of 106 euros per share, a discount of 7.1% compared to the closing price Monday evening (114.10 euros).
* EUROFINS SCIENTIFIC EUFI.PA reported on Tuesday a turnover in the second half of 3.31 billion euros.
* EDENRED EDEN.PA reported on Tuesday an annual EBITDA of 1.08 billion euros, just above expectations. The group also announced the acquisition of the RB and Spirii groups.
➦ Edenred announces record annual profit in 2023
* PLUXEE PLX.PA announced on Tuesday that it had successfully placed a bond issue amounting to 1.1 billion euros.
* L’OREAL OREP.PA – Berenberg raises its recommendation from “hold” to “buy”.
* ROCHE ROG.S plans to sell its treatment for lung diseases, Esbriet, the Bloomberg agency reported Monday evening, citing sources close to the matter.
* MUNICH RE MUVGn.DE announced on Tuesday a 12% drop in its net profit in the fourth quarter, a smaller fall than analysts expected and which allows the reinsurer to exceed its profit target for the entire year.
* PUMA PUMG.DE said on Tuesday it expected a weaker first half of 2024, with negative currency effects continuing to weigh on results.
* GAZTRANSPORT & TECHNIGAZ (GTT) GTT.PA reported on Monday a 45.6% increase in its Ebitda for the year 2023, driven by the absence of delays in the production of ships.
➦ GTT announces increased results in 2023
* STRAUMANN STMN.S – The dental implant manufacturer announced on Tuesday that it expects its sales to grow in 2024 at a level similar to that of last year, adopting a cautious stance in a context of prolonged economic uncertainty.
* CRODA INTERNATIONAL CRDA.L – The chemicals supplier on Tuesday reported annual profits above consensus and said it sees signs of rebounding demand in its consumer products unit in the new year.
* ABRDN ABDN.L reported a drop in its annual operating profit for 2023 on Tuesday, as the group implements significant cost cuts to revive its performance.
* HIKMA PHARMACEUTICALS HIK.L – Merck MRK.N has received a letter indicating that the US unit of Hikma Pharmaceuticals has asked the FDA for authorization to use before expiration of a patent to sell a generic version of the drug Bridion.
* ASTRAZENECA AZN.L – FibroGen FGEN.O said it would regain AstraZeneca’s rights to anemia drug roxadustat in the United States and some other countries after the two companies agreed to end their collaboration.
THE FRANCE & INTERNATIONAL 7-DAY AGENDA:
(Written by Claude Chendjou and Corentin Chappron, edited by Blandine Hénault)